Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage 0 Breast Cancer|Stage IA Breast Cancer
Interventions: DRUG: Anastrozole|DRUG: Exemestane|OTHER: Laboratory Biomarker Analysis|DRUG: Letrozole|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Tamoxifen Citrate|DRUG: Toremifene Citrate
Sponsor: Fred Hutchinson Cancer Center
Collaborators: National Cancer Institute (NCI)